The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis
出版年份 2019 全文链接
标题
The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis
作者
关键词
-
出版物
BMC CANCER
Volume 19, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-04-25
DOI
10.1186/s12885-019-5602-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
- (2017) Po-Han Lin et al. Cancer Medicine
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics
- (2016) Naval Daver et al. Expert Review of Hematology
- Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome
- (2016) C Y Cher et al. Blood Cancer Journal
- Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype
- (2015) J.-S. Ahn et al. HAEMATOLOGICA
- ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
- (2015) P. Paschka et al. HAEMATOLOGICA
- High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis
- (2015) Hsiao-Wen Kao et al. Oncotarget
- Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype
- (2015) J.-S. Ahn et al. HAEMATOLOGICA
- ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
- (2015) P. Paschka et al. HAEMATOLOGICA
- Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
- (2015) Aline Renneville et al. Oncotarget
- Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics
- (2014) Jiří Mayer et al. BMC CANCER
- TET2mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns
- (2014) Frederik Damm et al. GENES CHROMOSOMES & CANCER
- TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD− mutations
- (2014) Xiaopeng Tian et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis
- (2014) Wen-Jian Liu et al. LEUKEMIA & LYMPHOMA
- Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1 and TET2 mutations
- (2014) Robert S Ohgami et al. MODERN PATHOLOGY
- DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients
- (2013) Velizar Shivarov et al. LEUKEMIA RESEARCH
- TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
- (2012) Verena I. Gaidzik et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
- (2011) K. H. Metzeler et al. BLOOD
- TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
- (2011) W.-C. Chou et al. BLOOD
- TET2 mutations in secondary acute myeloid leukemias: a French retrospective study
- (2011) O. Kosmider et al. HAEMATOLOGICA
- TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2011) Klaus H. Metzeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Landscape of TET2 mutations in acute myeloid leukemia
- (2011) S Weissmann et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission
- (2010) O. Nibourel et al. BLOOD
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
- (2010) Myunggon Ko et al. NATURE
- DNMT3AMutations in Acute Myeloid Leukemia
- (2010) Timothy J. Ley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent prognostic factors for AML outcome
- (2009) D. Grimwade et al. Hematology-American Society of Hematology Education Program
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started